Orthofix Medical Inc Dossier
|
SectorHealth Care IndustryHealth Care Equipment Beta (adjusted)0.77 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $9.21Price as of 1 Oct 2026 Data confidenceNot applicable Market Cap $375.1M Enterprise Value $492.9M Shares Outstanding 41M diluted Moat Rating None Next Earnings Date3 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Orthofix Medical Inc. is navigating a complex transitional period. While the company delivered a solid Q1 2026 earnings beat driven by disciplined cost management and distributor optimization, its near-term outlook has been severely pressured by regulatory headwinds. Specifically, the FDA's reclassification of non-invasive bone growth stimulators to Class II and subsequent CMS billing updates effective May 18, 2026, are expected to reduce average Medicare reimbursement rates by approximately 10%. Because the bone growth therapies business is a high-margin cash generator representing a significant portion of sales, this change has forced management to lower its full-year 2026 guidance, withdraw its three-year financial targets, and project negative free cash flow for the year. Consequently, while the core business remains fundamentally sound and undervalued on an asset basis, a 'Hold' recommendation is warranted until there is greater visibility on top-line stabilization and margin recovery. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$12.00 Mean target$15.50 High · most bullish analyst$18.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $12.0020% The bear case is triggered by further regulatory or reimbursement pressures from commercial payers following the CMS lead, or execution delays in the U.S. Spine and Biologics segments. If distributor transitions experience renewed friction or if the company fails to manage its operating expenses, adjusted EBITDA could fall below the revised $90 million floor. Continued cash burn would strain the balance sheet, forcing the stock down toward its 52-week lows. Base CaseCentral scenario $15.5055% Matches the consensus meanThe base case assumes Orthofix executes in line with its revised 2026 guidance, achieving net sales of $838 million to $848 million and adjusted EBITDA of $90 million to $93 million. Top-line growth will remain modest (around 3-5%) as the high-margin Restorative Therapies segment absorbs the 10% Medicare reimbursement cut. Free cash flow will remain negative for the full year, and the stock will trade sideways near its historical valuation multiples until the company establishes a clear path back to profitability and positive cash generation. Bull CaseUpside scenario $18.0025% The bull case centers on rapid productivity gains from the company's consolidated distributor network and successful new product rollouts. If the top 30 U.S. distributors (which grew 27% YoY in Q1 2026) continue to capture market share, and upcoming launches like VIRATA in H2 2026 outperform expectations, the company could offset the Medicare reimbursement headwinds. Operational leverage and cost synergies from the SeaSpine integration could expand EBITDA margins faster than anticipated, driving the stock toward the high end of analyst targets. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |